Price
3.52
+0.57%52W Range
Market Cap
₹9.08 Cr
Traded: ₹0.02 Cr (0.23%) 0.0x
Free Float: ₹4.20 Cr (0.49% of FF traded)
Volume · 60D trend
59.12 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +1.0% | +0.0% | +0.0% | -- | -- | Stable |
| Return | -- | -31.0% | -24.0% | -54.0% | -- | Stable |
| Profit | -- | -- | -- | -- | -280.0% | -- |
| Sales | +48.0% | +81.0% | +27.0% | -- | -90.0% | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 0 | 0 | 2 | 1 | 1 | 5 | 1 | 11 | 2 | 3 | 0 | 1 |
| Expenses | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 5 | 1 | 11 | 2 | 3 | 0 | 1 |
| Operating Profit | -0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OPM % | -- | -10.2% | -- | -- | 8.4% | -36.3% | 19.5% | 4.2% | 10.1% | 1.1% | 4.2% | 4.3% | 18.5% | 20.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 53.9% | 22.2% | 0.0% | 0.0% | 27.8% |
| Net Profit | -0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.0 | -0.0 | -0.0 | -0.0 | 0.1 | -0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 |
| Sales Growth (YoY) | -100.0% | -34.8% | -100.0% | -100.0% | 68.7% | -88.1% | -40.7% | 46.3% | 266.7% | 1222.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -100.0% | -- | -- | -100.0% | 23.7% | 5.5% | -73.0% | 378.8% | -91.3% | 426.4% | -33.3% | 1100.0% | -68.6% | -- |
| OP Growth (YoY) | -107.1% | 81.6% | -116.0% | -120.0% | 40.0% | -476.9% | 177.8% | 42.9% | 100.0% | -27.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | 88.9% | -125.0% | 0.0% | -128.6% | 128.6% | -296.0% | 25.0% | 100.0% | -23.1% | 44.4% | -35.7% | 180.0% | -72.2% | -- |
| Profit Growth (YoY) | -107.0% | 82.0% | -116.0% | -120.0% | 40.0% | -917.0% | 212.0% | 43.0% | 100.0% | -54.0% | 60.0% | 600.0% | 150.0% | 425.0% |
| EPS Growth (YoY) | -100.0% | 84.2% | -120.0% | -125.0% | -44.4% | -480.0% | 42.9% | -33.3% | 125.0% | -54.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 100.0% | -50.0% | 0.0% | -140.0% | 126.3% | -290.0% | 25.0% | -11.1% | 80.0% | -28.6% | -41.7% | 200.0% | -63.6% | -- |
| OP Margin | -- | -10.2% | -- | -- | 8.4% | -36.3% | 19.5% | 4.2% | 10.1% | 1.1% | 4.2% | 4.3% | 18.5% | 20.9% |
| Net Margin | -- | -10.2% | -- | -- | 8.4% | -36.3% | 19.5% | 4.2% | 10.1% | 0.5% | 3.7% | 4.3% | 18.5% | 15.1% |
| Material Cost % | -- | 80.7% | -- | -- | 88.0% | 95.6% | 68.8% | 93.7% | 79.8% | 93.4% | 94.4% | 94.8% | 55.6% | 65.0% |
| Employee Cost % | -- | 12.5% | -- | -- | 1.2% | 14.1% | 0.0% | 1.5% | 2.0% | 2.2% | 0.5% | 0.0% | 11.1% | 5.0% |
| P/S | 10.32 | 3.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.30 | 0.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Quarterly Results June 30, 2026
Quarterly Results June 30, 2026
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Quarterly Results June 30, 2026
Resignation of Directors
Reg 74(5)
Closure of Trading Window
AGM
Appointment of Ms. Shruti Sharma (M. No.: A52723) as Company Secretary and Compliance Officer of the Company w.e.f. 05th June, 2026.
Reg 24A
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/06/2026 ,inter alia, to consider and approve Details related to AGM
Unable to conduct Board Meeting on 18th May 2026
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve AGM
Audited Financial Results for the Quarter and Year ended March 2026
Audited Financial Results along with Auditors Report for the Quarter and Year ended March 2026
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2026 ,inter alia, to consider and approve Audited Results and Audit Report
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 ,inter alia, to consider and approve Audited Financial Result ....
Certificate under Reg 74(5)
Closure of Trading Window
Independent Directors Meeting
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/03/2026 ,inter alia, to consider and approve Independent Directors Meeting
Un-Audited Financial Results (UFR) for the Third quarter and Nine Months ended December 31, 2025, along with the Statutory Auditors' Limited Review Report.
Un-Audited Financial Results for the Third quarter and Nine months ended December 31, 2025, along with the Statutory Auditors Limited Review Report.
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Unaudited financial ....
Certificate under Reg 74(5) of SEBI for quarter ended on December 31, 2025
Intimation for closure of trading window
Revised Financial Result for the quarter ended September 30, 2025.
Outcome of the meeting of board of directors held on Friday, November 14, 2025.
As attached.
Meeting of Board of directors further adjourned to November 14, 2025.
The Board meeting of the company further adjourned on Thursday November 13, 2025 due to unavoidable circumstances.
Board meeting of the company adjourned to tomorrow i.e. November 12, 2025 due to unavoidable circumstances.
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Unaudited financial ....
As attached.
As attached.
As attached.
Submission of annual report of the company.
As attached
As attached
Un-Audited Financial Results (UFR) for the first quarter ended June 30, 2025, along with the Statutory Auditors' Limited Review Report.
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve Unaudited financial ....
Compliances certificate under Regulation 74 (5) of SEBI (DP) Regulation.
Intimation of Closure of Trading window for the quarter ended June 30, 2025.
Secretarial Compliance Report of the company for the year ended on March 31, 2025.
As attached
As attached
Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their ....
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve audited Financial Results ....
Natural Biocon (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 ,inter alia, to consider and approve Audited Financial Result ....
Compliance certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018.